L26/P-793 Long-term morbidity and mortality in lean women with polycystic ovary syndrome versus lean ovulatory controls: a 37-year prospective cohort study
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.1120 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von N. Kugelman und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Do young lean women with polycystic ovary syndrome (PCOS) have increased long-term morbidity or mortality compared with lean ovulatory controls over prolonged prospective follow-up? Summary answer Lean women with PCOS showed no increased long-term morbidity or mortality compared with lean ovulatory controls during up to 37 years of prospective follow-up. What is known already PCOS is associated with insulin resistance and increased cardiometabolic risk, particularly among obese women, in whom adiposity substantially amplifies metabolic abnormalities. Lean women with PCOS may exhibit hormonal and metabolic alterations, including insulin resistance, yet reported cardiometabolic risk in this phenotype remains inconsistent. Existing studies are largely limited by short follow-up, retrospective design, or reliance on BMI measured later in life rather than in early adulthood. Consequently, whether lean PCOS confers increased long-term morbidity independent of obesity remains unclear. Strong prospective data evaluating long-term health outcomes specifically in lean women with PCOS are scarce. Study design, size, duration This prospective cohort study followed women recruited between 1987 and 2005 for up to 37 years, with follow-up through 2024. The analysis included 262 lean women with polycystic ovary syndrome and 24 lean ovulatory controls. Lean status was defined at enrolment by body mass index 18.5–24.9 kg/m². The study assessed long-term morbidity and mortality outcomes. Participants/materials, setting, methods Baseline data included age, body mass index, hormonal profile, and metabolic markers. Long-term follow-up systematically assessed mortality and a broad range of chronic conditions, including cardiometabolic, endocrine, neurological, respiratory, psychiatric, oncologic, gastrointestinal, rheumatologic, renal, and hepatic disorders. Primary outcomes were long-term morbidity and mortality. Statistical analyses included t-tests, chi-square or Fisher’s exact tests, and multivariable logistic regression adjusting for age at enrolment and follow-up duration. Main results and the role of chance At enrolment, age (28.3±6.7 vs 28.9±6.4 years, p = 0.67) and body mass index (21.5±2.4 vs 22.0±1.9 kg/m², p = 0.25) were similar between lean women with PCOS and lean ovulatory controls. Lean PCOS patients demonstrated lower free testosterone (7.4±4.7 vs 9.5±4.3 nmol/L, p = 0.037), lower DHEA (24.2±16.3 vs 32.5±17.2 µmol/L, p = 0.019), and lower fasting glucose (3.5±1.9 vs 4.4±0.5 mmol/L, p < 0.001). Fasting insulin levels and lipid profiles did not differ significantly between groups. At follow-up, mean age was 58.7±8.3 years in the PCOS group and 61.4±6.7 years in controls (p = 0.12). Mortality was low and not significantly different (2.7% vs 0%, p = 1.0). Lean PCOS patients exhibited numerically higher prevalences of non-insulin dependent diabetes, hypertension, dyslipidemia, hypothyroidism, respiratory disease, malignancy, neurological and psychiatric disorders; however, none of these differences reached statistical significance. Multivariable logistic regression adjusting for age at enrolment and follow-up duration demonstrated no independent association between PCOS status and long-term morbidity or mortality. No consistent cardiometabolic or non-metabolic risk pattern attributable to PCOS was identified. Limitations, reasons for caution This single-center observational study is limited by the small number of lean ovulatory controls, reducing statistical power and generalizability. Loss to follow-up of 17% may have introduced selection bias. Even longer follow-up may be required to detect very late-onset morbidity differences. Wider implications of the findings These findings suggest that lean women with PCOS may not share the long-term disease burden observed in obese PCOS phenotypes. They support phenotypic stratification and a more individualized approach to long-term monitoring and risk assessment in PCOS care. Trial registration number No
Zitieren
APA
Kugelman, N., Morris, D., & Dahan, M. (2026). L26/P-793 Long-term morbidity and mortality in lean women with polycystic ovary syndrome versus lean ovulatory controls: a 37-year prospective cohort study. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1120
Vancouver
Kugelman N, Morris D, Dahan M. L26/P-793 Long-term morbidity and mortality in lean women with polycystic ovary syndrome versus lean ovulatory controls: a 37-year prospective cohort study. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1120
BibTeX
@article{Kugelman2026,
author = {Kugelman, N. and Morris, D.V. and Dahan, M.H.},
title = {L26/P-793 Long-term morbidity and mortality in lean women with polycystic ovary syndrome versus lean ovulatory controls: a 37-year prospective cohort study},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.1120}
}
EUVIMED